Immunotherapy – 2072. Therapeutic effect and higher safety profile for allergic asthma in Cuban patients with sublingual immunmotherapy using tropical domestic mite allergen vaccines

Almarales, Raúl Lázaro Castro; Castelló, Mirta Álvarez; Díaz, Mercedes Ronquillo; León, Mayda González; Rosado, Alexis Labrada; Canosa, José Severino Rodríguez; Viltres, Bárbara Ivonne Navarro; Diaz, Yunia Olivia; Morejón, Maytee Mateo

doi:10.1186/1939-4551-6-s1-p154

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The treatment was considered effective in 77% of patients. Local reactions were noted only in 0.43% of administrations and no systemic reactions were observed [ 41 ].…”

Section: Reviewmentioning

confidence: 99%

Current status and future perspectives of immunotherapy in Latin America and Cuba

Rodríguez¹,

Labrada

Almarales

et al. 2014

World Allergy Organization Journal

Self Cite

View full text Add to dashboard Cite

Most Latin-American countries use subcutaneous immunotherapy (SCIT) extracts from the United States and Europe and sublingual immunotherapy (SLIT) from Europe, with the exception of Argentina, Brazil, Cuba and Mexico. The number of researches on immunotherapy (IT) in Latin America has increased extensively in the last years. Only few Latin American countries have their own guidelines on IT, and, in general, the economic resources for medical research on IT are still low in the area. A global approach for the future of IT in Latin America includes to improve standardization, quality control and the production of allergen products, to develop IT guidelines and clinical investigation by the highest number of countries, to improve the regulatory status for allergens products in the area, and to expand IT accessibility for low-income patients. In Cuba, the first registered allergen vaccines were developed and registered in 2006: a standardized (in biologic units) and freeze dried product for SCIT, with a sublingual version developed in 2009. As much as 23.000 IT treatments were applied in 2011, all provided to patients free of charge. In 2012, Cuban researchers developed an IT vaccine with adjuvant for subcutaneous route, which uses Neisseria meningitidis proteoliposome as an adjuvant, added to the purified Dermatophagoides siboney major allergens: Der s1 and Der s2. Since December 2012, this vaccine is in Phase I clinical trial, evaluating its safety, tolerability and immunogenicity in asthmatic patients sensitized to this allergen. Cuban perspectives on IT includes to work on new indications for IT, to investigate the preventive effect and cost-effectiveness for the current vaccines, to develop new products with mixed formulas of house dust mites for SLIT, to complete the phase I and II clinical study for dust mite plus adjuvant vaccine, to develop allergen vaccines for fungi allergy and to complete the Cuban guideline for allergen IT management.

show abstract

“…The treatment was considered effective in 77% of patients. Local reactions were noted only in 0.43% of administrations and no systemic reactions were observed [ 41 ].…”

Section: Reviewmentioning

confidence: 99%

Current status and future perspectives of immunotherapy in Latin America and Cuba

Rodríguez¹,

Labrada

Almarales

et al. 2014

World Allergy Organization Journal

Self Cite

View full text Add to dashboard Cite

show abstract

Sublingual immunotherapy for asthma

Normansell

Kew

Bridgman

2015

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Lack of data for important outcomes such as exacerbations and quality of life and use of different unvalidated symptom and medication scores have limited our ability to draw a clinically useful conclusion. Further research using validated scales and important outcomes for patients and decision makers is needed so that SLIT can be properly assessed as clinical treatment for asthma. Very few serious adverse events have been reported, but most studies have included patients with intermittent or mild asthma, so we cannot comment on the safety of SLIT for those with moderate or severe asthma. SLIT is associated with increased risk of all adverse events.

show abstract